Ever Source Wealth Advisors, LLC Cyma Bay Therapeutics, Inc. Transaction History

Ever Source Wealth Advisors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.63 - $24.47 $3,498 - $6,778	277 Added 54.42%	786 $18,000
Q3 2023 Nov 03, 2023	SELL	$10.86 - $17.62 $966 - $1,568	-89 Reduced 14.88%	509 $7,000
Q2 2023 Aug 04, 2023	SELL	$7.47 - $10.95 $605 - $886	-81 Reduced 11.93%	598 $6,000
Q1 2023 May 11, 2023	SELL	$5.88 - $9.59 $3,727 - $6,080	-634 Reduced 48.29%	679 $5,000
Q4 2022 Feb 09, 2023	SELL	$3.22 - $6.27 $1,252 - $2,439	-389 Reduced 22.86%	1,313 $8,000
Q2 2022 Aug 01, 2022	BUY	$1.72 - $3.39 $2,927 - $5,769	1,702 New	1,702 $5,000
Q1 2022 May 25, 2022	SELL	$2.77 - $3.64 $2,908 - $3,822	-1,050 Closed	0 $0
Q4 2021 Feb 07, 2022	BUY	$3.23 - $4.6 $3,391 - $4,830	1,050 New	1,050 $4,000

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Ever Source Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Ever Source Wealth Advisors, LLC with notifications on news.